---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028700"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2026-06-15T20:30:17+00:00"
generated_at: "2026-06-15T20:31:24.033063+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dyadic highlights accelerated C1 platform interest amid Ebola preparedness and commercial adoption

## Summary
- C1 platform can produce purified antigen or monoclonal antibody in ~15 days, says company.
- Collaborations: Scripps Research (Ebola, hantaviruses); CEPI Ebola funding proposals; Fondazione Biotecnopolo di Siena (Ebola, hantavirus antibodies).
- Commercial milestones: recombinant human albumin via Proliant Health; recombinant DNase I via Fermbox Bio; bovine chymosin via Inzymes.
- Estimated addressable market >$25B across life sciences, food/nutrition, bioindustrial applications.
- DYAI-100 clinical study showed C1-produced antigens were generally safe and well tolerated.

## SEC filing metadata
- accession: 0001493152-26-028700
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2026-06-15T20:30:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000149315226028700/0001493152-26-028700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000149315226028700/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028700
- JSON: https://secwatch.observer/filing/0001493152-26-028700.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.